Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted at the Gynecological emergency Unit at Hospital de Clínicas de Porto Alegre scheduled for uterine evacuation with \<12 weeks of gestation.~Exclusion Criteria:~* patients who do not wish to participate in the project;~* patients with ectopic pregnancy;~* patients with comorbidities (heart failure congestive, chronic obstructive pulmonary disease);~* patients with hypovolemic shock;~* patients with cervical incompetence;~* patients with infected miscarriage/abortion (presence of fever, pus from the cervix, leukocytosis \[\> 14000\]);~* patients with twin pregnancy;~* patients with Marfan syndrome;~* patients allergic to misoprostol;~* patients with coagulopathy;~* patients with opening of cervical internal os (4 mm of dilatation at the time of consultation);~* patients with previous surgery of the cervix (conization);~* patients with concomitant use of IUDs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Misoprostol 400 µg (Type: ACTIVE_COMPARATOR): Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
- Misoprostol 200 µg (Type: EXPERIMENTAL): Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).